David Moore

About David Moore

David Moore is a non-employee director of Corvus Pharmaceuticals (CRVS), appointed October 2, 2025, with a Class III term through the 2028 annual meeting . He serves concurrently as Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., with a 27-year industry background spanning strategy, commercial, market access, BD and investing; he holds an MBA in Marketing from Lehigh University and a BS in Biology from Towson University . Tenure on CRVS’s board began October 2, 2025 .

Past Roles

External Roles

Board Governance

• Committee assignments: Compensation Committee member and Nominating & Corporate Governance Committee member, effective October 2, 2025 .
• Independence: Appointed to committees that, per CRVS policy and Nasdaq rules, are comprised of independent directors; CRVS states committee independence requirements in its proxy and charters . Non-employee director status noted in appointment 8‑K .
• Board structure and practices: Independent directors meet in executive session; Board encourages annual meeting attendance; independence assessed under Nasdaq requirements .
• Years of service: Appointed October 2, 2025 (Class III) .
• Chair roles: None disclosed; committee chairs as of 2024 were Dr. Thompson (Compensation) and Mr. Gould (Nominating); Moore not identified as chair .

Fixed Compensation

• Director Compensation Program terms: Annual cash retainers and committee fees as specified; Initial Grant of 30,000 options on first appointment; Annual Grant of 15,000 options at each annual meeting for continuing directors .
• Change-in-control: All director equity awards vest in full immediately prior to a change in control .

Performance Compensation

• Equity awards are options; there is no disclosure of RSUs/PSUs for directors in 2024. Non-employee directors received option grants with grant-date fair values; the program specifies Initial and Annual Grants with fixed share counts and time-based vesting .

No performance-linked metrics (TSR/revenue/EBITDA) are disclosed for director pay; equity is time‑based options per program .

Other Directorships & Interlocks

• Current outside executive roles: EVP US Operations at Novo Nordisk A/S; President at Novo Nordisk Inc. .
• Interlocks: No compensation committee interlocks reported for 2024; Moore’s appointment 8‑K discloses committee membership and standard indemnification without interlocks or related transactions .
• Potential interlock considerations: Concurrent senior role at Novo Nordisk could create future related‑party considerations if CRVS engages in transactions with Novo; none are disclosed at appointment .

Expertise & Qualifications

• Strategic/commercial leadership: Led Novo’s US business and GLP‑1 franchise; deep expertise in market access and BD .
• Investment and operating experience: Life-science PE at Gurnet Point; operating roles at Roivant/Lysovant and Cempra .
• Education: MBA in Marketing (Lehigh University); BS in Biology (Towson University) .

Equity Ownership

Beneficial ownership table as of March 31, 2025 does not include Moore (appointed October 2025); his grants post-appointment are disclosed in the 8‑K .

Governance Assessment

• Positive signals:

  • Independent, non-employee director with appointment to Compensation and Nominating committees, indicating board’s independence determination under Nasdaq rules .
  • Strong commercial and BD pedigree (Novo GLP‑1 franchise leadership) relevant to partnering and commercialization strategy for CRVS .
  • Director equity aligned via options; Insider Trading Policy prohibits hedging/pledging, supporting alignment and risk controls .

• Watch items / RED FLAGS:

  • Change-in-control immediate vesting of director equity may reduce retention incentives through a transaction; standard but noteworthy for alignment analysis .
  • Concurrent executive role at Novo Nordisk could present future related‑party or conflict considerations if CRVS pursues collaborations or transactions with Novo; none disclosed at appointment .
  • No attendance record yet (appointed after FY2024); monitor FY2025+ attendance and engagement .

• Compensation structure implications:

  • Cash retainer plus option-based equity maintains at‑risk exposure; absence of RSUs/PSUs suggests lower guaranteed equity and more sensitivity to share price performance .
  • Committee fees modest; no meeting fees disclosed—comp aligns with typical small-cap biotech governance frameworks .

• Procedural safeguards:

  • Board committees operate under charters; independence and financial literacy requirements documented; executive sessions of independent directors in place .
  • Clawback policy adopted per Nasdaq/Rule 10D‑1 (officer-focused); insider trading policy robust for directors .

Related Party Transactions

• None involving David Moore disclosed at appointment; 8‑K covers compensation program participation and indemnification only .
• Proxy period related-party transactions involve other parties (e.g., OrbiMed participation in May 2024 offering) but do not include Moore .

Compensation Committee Analysis

• Composition updated to include Moore as member effective October 2, 2025; chair remained Dr. Thompson as of 2024 proxy .
• Interlocks: None disclosed for 2024; no consultant conflicts disclosed in proxy; committee charter governs duties .

---

Sources

• Appointment and compensation terms: CRVS Form 8‑K (Oct 2, 2025) .
• Background, external roles, education: CRVS press release (Oct 2, 2025) .
• Board independence, executive sessions: CRVS 2025 Proxy (DEF 14A) .
• Committee structures, chairs, charters: CRVS 2025 Proxy (DEF 14A) .
• Director compensation program, fees, grants, vesting, CIC treatment: CRVS 2025 Proxy (DEF 14A) .
• Insider trading policy (hedging/pledging prohibition): CRVS 2025 Proxy (DEF 14A) .
• Indemnification agreements: CRVS 2025 Proxy (DEF 14A) .
• Board meeting attendance practice (FY2024): CRVS 2025 Proxy (DEF 14A) .
• Beneficial ownership table (as of Mar 31, 2025): CRVS 2025 Proxy (DEF 14A) .